Declaring topline PhIII win, Takeda revives blockbuster hopes for its troubled multiple myeloma drug
Five months after dismal trial results convinced Takeda to scrap an entire Phase III program for their multiple myeloma drug Ninlaro, the Japanese giant announced a different late-stage trial has met its primary endpoint — although they have yet to release any data.
Ninlaro improved progression-free survival as a first-line maintenance treatment in a placebo trial of 706 patients who have not received a stem cell transplant and responded to 6-12 months of treatment, Takeda announced.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
